GlobeNewsWire
15 Oct 2026, 00:29 UTC · 1w ago
Impact · against what's priced in
Interpace Biosciences provided a preliminary Q3 2026 revenue range of $10.1 million to $10.4 million. As a factual update without a prior benchmark or guidance for this specific period, it serves as a neutral data point for the market.
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
What the story claims
1 claim · scored −1 bearish … +1 bullish · 1 new · 0 priced in
Interpace Biosciences expects preliminary unaudited Q3 2026 revenue to range between $10.1 million and $10.4 million.
Newannounced today, Oct 14
So whatThe $300k variance in this range will be a primary focus for analysts during the full Q3 earnings print.
More positive than 68% of claims this week
Which stocks this story touches
Continue reading
5 related stories
Near neutral — 91% of ticker scores this week are stronger
The company provided preliminary revenue guidance, which is a neutral factual update without specific positive or negative commentary.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Zacks Investment Research
54m ago
